Welcome to our dedicated page for BlackRock Tech and Private Equity Term news (Ticker: BTX), a resource for investors and traders seeking the latest updates and insights on BlackRock Tech and Private Equity Term stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BlackRock Tech and Private Equity Term's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BlackRock Tech and Private Equity Term's position in the market.
Brooklyn ImmunoTherapeutics (BTX) has signed a non-binding letter of intent to acquire Novellus Therapeutics for approximately $125 million, comprising $17.4 million in cash and $107.6 million in BTX stock. The acquisition aims to enhance Brooklyn's gene editing and cell therapy capabilities and is expected to close by July 15, 2021. The completion depends on due diligence and various approvals, with Brooklyn having over $43 million in cash available. This acquisition aligns with Brooklyn's strategy to lead in next-generation stem cell therapy.
BROOKLYN, N.Y., June 09, 2021 - Brooklyn ImmunoTherapeutics (BTX) announced its addition to the Russell 3000 Index, effective June 28, 2021. This recognition enhances the visibility of its innovative therapies targeting cancer, blood disorders, and monogenic disorders. With approximately $10.6 trillion in assets benchmarked against Russell’s U.S. Indexes, membership opens new opportunities for investment. The company’s lead program, IRX-2, has shown promising results in Phase 2A trials for head and neck cancer, indicating a potential overall survival benefit.
BROOKLYN, N.Y., June 08, 2021 – Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced the appointment of Dr. Kevin A. D’Amour as Chief Scientific Officer. Dr. D’Amour, previously Chief Scientific Officer at ViaCyte, brings over 100 patents and extensive experience in cell and gene therapy. CEO Howard J. Federoff highlighted Dr. D’Amour's expertise as pivotal for Brooklyn's pioneering work in innovative cancer treatments. Brooklyn is advancing therapies for cancer and blood disorders, utilizing exclusive technologies from Factor Bioscience and Novellus, with its lead program studying IRX-2 in head and neck cancer.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) has established a new research and development center in Cambridge, Massachusetts, co-locating with Factor Bioscience and Novellus Therapeutics. This facility will focus on mRNA-based gene editing and cellular therapies for cancer and rare blood disorders, leveraging exclusive licenses from both companies. Key technologies include mRNA cell reprogramming, mRNA-based gene editing, and a nanolipid delivery system. Brooklyn's leading program is IRX-2 for head and neck cancer, which showed promising overall survival benefits in clinical trials.
BROOKLYN ImmunoTherapeutics (NYSE American: BTX) updates investors on its innovative treatments targeting cancer and blood disorders. Key highlights include the advancement of IRX-2, a Phase 2 asset for head and neck cancer, which has shown promising overall survival benefits. The company also announced a new license for mRNA cell reprogramming technology aimed at enhancing treatment options for various tumors and genetic disorders. Brooklyn aims to solidify its financial position while exploring new therapeutic avenues.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) has successfully completed a $20 million financing aimed at advancing its mRNA gene editing and cell therapies technology, licensed from Factor Biosciences and Novellus Therapeutics. The funds will facilitate the translation of this technology into clinical programs targeting orphan diseases, such as sickle cell anemia and familial amyloidosis. The licensed platform includes novel mRNA-based methods for gene editing and cellular reprogramming, enhancing therapeutic efficiency while minimizing off-target effects. Brooklyn's leading program is IRX-2, currently undergoing Phase 2A trials for head and neck cancer.
Brooklyn ImmunoTherapeutics (BTX) announced the appointment of Dr. Michael Andreeff to its Scientific Advisory Board, effective May 21, 2021. Dr. Andreeff, a leading expert in leukemia treatment and molecular hematology at MD Anderson Cancer Center, brings extensive experience in developing therapies for blood disorders. His expertise is anticipated to enhance Brooklyn's gene editing and cell therapy initiatives, especially following the company’s recent licensing agreement for gene editing technology. Brooklyn is currently advancing its IRX-2 program for head and neck cancer, demonstrating promise in clinical trials.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced a conference call scheduled for May 25, 2021, at 4:30 p.m. ET. Participants must pre-register to receive the dial-in information. The call will address the company's exploration of cytokine and gene editing therapies for cancer and blood disorders. The lead program, IRX-2, is undergoing a Phase 2A trial, showing promising survival benefits for head and neck cancer patients. The company aims to advance treatments through newly acquired gene editing licenses.
Brooklyn ImmunoTherapeutics (BTX) has announced a publication in Breast Cancer Research showcasing the effectiveness of multiplex immunofluorescence (mIF) in assessing immunological activity of IRX-2 in early-stage breast cancer. This methodology offers improved estimates of treatment-related effects compared to conventional methods. IRX-2, a cytokine-based therapy, has shown promise in increasing immune cell infiltration, particularly when combined with PD-L1-targeted therapies. Brooklyn has launched a Phase 2 trial for IRX-2 in triple-negative breast cancer, with approximately 30 patients expected to participate.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) announced the appointment of Dr. Erich Mohr to its Board of Directors, effective May 7, 2021. Dr. Mohr brings a wealth of experience from leading life sciences firms, focusing on creating value in board and executive roles. He expressed enthusiasm for joining Brooklyn at a pivotal growth stage, particularly due to the promising clinical trials of IRX-2, a cytokine-based treatment for cancer. Additionally, the company has acquired advanced gene editing technology, enhancing its capabilities in oncology and blood disorders.
FAQ
What is the current stock price of BlackRock Tech and Private Equity Term (BTX)?
What is the market cap of BlackRock Tech and Private Equity Term (BTX)?
